- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01631877
Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver
June 2, 2018 updated by: Institute of Liver and Biliary Sciences, India
After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled.
The baseline Doppler parameter will be recorded and the patient will be randomized into either interventional (acenocoumarol) or placebo group along with first five days of subcutaneous Low Molecular Weight Heparin inj.
Enoxaparin in the interventional arm and placebo injection in the control arm.
Every 3 monthly the Doppler screening for recanalization of portal vein thrombus will be done with monitoring of International Normalized Ratio (INR)with target INR 2-3.
Both the groups will receive the therapy for one year irrespective of the Doppler findings in relation to portal vein thrombus re-canalization.Then one year drug free monitoring will be done in both the groups as per the primary or secondary outcome. .
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Delhi
-
New Delhi, Delhi, India, 110070
- Institute of Liver and Biliary Sciences.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A clinical, radiological or histologic diagnosis of cirrhosis
- Partial or total Portal vein thrombus (evidence of chronic thrombus)
- Informed consent to participate in the study
Exclusion Criteria:
- Acute thrombus in Portal vein
- Hepatocellular carcinoma or any other malignancy,
- Hypercoagulable state other than the liver disease related
- DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
- Base line INR >2
- Child Turcott Pugh score>11
- Recent peptic ulcer disease
- History of Hemorrhagic stroke
- Pregnancy.
- Uncontrolled Hypertension
- Age>70 yrs
- Non responders to beta-blocker requiring Endoscopic Variceal Ligation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: enoxaparin with acenocoumarol
Patients will receive enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg with titration of dose to maintain a target INR of 2-3.intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR.After achieving the target INR this is to be repeated every 4th weekly.
The Doppler Ultra Sonography screening will be done every 3monthly to assess the recanalization of portal vein thrombus but the medications will be continue for one year irrespective of recanalization.
|
enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
|
Placebo Comparator: Placebo
Injection placebo will be given for 5 days along with placebo tablets.
|
injection placebo will be given for 5 days along with placebo tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportions of patients who will achieve Recanalization of thrombus (complete i.e No thrombus is seen or partial i.e up to 50% of the lumen become patent.)on oral anticoagulant acenocoumarol during the study period of 2 year from randomization.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportions of patients who will show improvement in Child Turcott Pugh (CTP) (>2 points)in both groups
Time Frame: 2 years
|
2 years
|
Proportions of patients who will show improvement in Model for End Stage Liver Disease (MELD)(>4 points)in both groups
Time Frame: 2 years
|
2 years
|
Proportions of patients who will achieve reduction in liver stiffness > 5 Kpa by transient elastography in both groups
Time Frame: 2 years
|
2 years
|
Proportions of patients will show decrease in hepatic decompensation i.e hepatic encephalopathy,ascites,hepato renal syndrome,variceal bleed,jaundice and coagulopathy in both groups.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
June 1, 2017
Study Registration Dates
First Submitted
June 15, 2012
First Submitted That Met QC Criteria
June 28, 2012
First Posted (Estimate)
June 29, 2012
Study Record Updates
Last Update Posted (Actual)
June 6, 2018
Last Update Submitted That Met QC Criteria
June 2, 2018
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ILBS- PVT-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Portal Vein Thrombosis
-
Università degli Studi dell'InsubriaOttawa Hospital Research InstituteUnknownPortal Vein Thrombosis | Mesenteric Vein Thrombosis | Splenic Vein ThrombosisCanada, Italy
-
University of AlbertaSanofi; Edmonton Civic Employees Research FundTerminatedPortal Vein Thrombosis | Splenic Vein ThrombosisCanada
-
Assiut UniversityNot yet recruitingPortal Vein Thrombosis
-
University Hospital Inselspital, BerneWithdrawnThrombosis Portal Vein
-
Instituto Nacional de Ciencias Medicas y Nutricion...RecruitingPortal Vein ThrombosisMexico
-
Nihon Pharmaceutical Co., LtdCompletedPortal Vein ThrombosisJapan
-
Postgraduate Institute of Medical Education and...RecruitingPortal Vein Thrombosis | Anticoagulants and Bleeding Disorders | Hepatic Vein Thromboses | Hepatic Venous Outflow Obstruction | Portal Hypertension, Noncirrhotic | Portal Vein Occlusion | Portal Vein Embolism | JAK2 Mutation | CALR Gene Mutation | Prothrombin G20210AIndia
-
Assiut UniversityNot yet recruitingPortal Vein Thrombosis
-
University of Maryland, BaltimoreInari MedicalNot yet recruitingThrombosis | Thrombectomy | Portal Vein
-
Elvan Onur KirimkerAnkara University; Ankara Güven HospitalCompletedLiver Transplant; Complications | Portal Vein Thrombosis
Clinical Trials on Enoxaparin with acenocoumarol
-
Universidad San JorgeRoche DiagnosticsCompletedPharmacogenetics | Anticoagulant | Medication Therapy Management | Community Pharmacy Services | Drug Utilization ReviewSpain
-
University Medical Center GroningenTerminatedLong-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism (Longheva)Neoplasms | Venous ThromboembolismNetherlands, United States, Canada, Italy, Germany
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsSpain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
-
Vivencio BarriosBayerCompletedAtrial Fibrillation and Flutter
-
Instituto de Investigación Hospital Universitario...CompletedAtrial Fibrillation | Venous Thromboses | Cardiac Valve DiseaseSpain
-
Centre Hospitalier Universitaire de Saint EtienneRecruitingPulmonary Arterial HypertensionFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Erasmus Medical Center; VU University of AmsterdamUnknownVentricular Thrombosis Mural Following Myocardial InfarctionNetherlands
-
Indonesia UniversityPT Metiska FarmaCompleted
-
Semmelweis University Heart and Vascular CenterUnknownCerebrovascular Accident | Prosthetic Cardiac Valve Thrombosis | Prosthetic Valve MalfunctionHungary
-
Oregon Health and Science UniversityNational Trauma Research Institute; Medical Research Foundation, OregonCompleted